Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer a randomized clinical trial

JAMA - Journal of the American Medical Association

Volumn 317, Issue 23, 2017, Pages 2392-2401

  Venook, Alan P ^a   Niedzwiecki, Donna ^b   Lenz, Heinz Josef ^c   Innocenti, Federico ^d   Fruth, Briant ^e   Meyerhardt, Jeffrey A ^f   Schrag, Deborah ^f   Greene, Claire ^a   O'Neil, Bert H ^g   Atkins, James Norman ^h   Berry, Scott ⁱ   Polite, Blase N ^j   O'Reilly, Eileen M ^k   Goldberg, Richard M ^l   Hochster, Howard S ^m   Schilsky, Richard L ⁿ   Bertagnolli, Monica M ^o   El Khoueiry, Anthony B ^c   Watson, Peter ^p   Benson, Al B ^q   Mulkerin, Daniel L ^r   Mayer, Robert J ^f   Blanke, Charles ^s   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e MAYO CLINIC CANCER CENTER   (United States)

^f DANA FARBER CANCER INSTITUTE   (United States)

^g INDIANA UNIVERSITY   (United States)

^h NSABP Foundation Inc   (United States)

ⁱ UNIVERSITY OF TORONTO   (Canada)

^j UNIVERSITY OF CHICAGO   (United States)

^k MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^l OHIO STATE UNIVERSITY   (United States)

^m YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁿ AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

^o BRIGHAM AND WOMEN S HOSPITAL   (United States)

^p Lenoir Memorial Hospital   (United States)

^q NORTHWESTERN UNIVERSITY   (United States)

^r UNIVERSITY OF WISCONSIN MADISON   (United States)

^s OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; PLATINUM COMPLEX;

ACNE; ADULT; ADVANCED CANCER; AGED; ARTERY THROMBOSIS; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; FATIGUE; FEMALE; HEMATOLOGIC DISEASE; HUMAN; HYPERTENSION; LETHARGY; MAJOR CLINICAL STUDY; MALAISE; MALE; METASTATIC COLORECTAL CANCER; ONCOGENE K RAS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; VERY ELDERLY; WILD TYPE; ANALOGS AND DERIVATIVES; CANADA; CLINICAL TRIAL; COLORECTAL NEOPLASMS; DISEASE FREE SURVIVAL; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; ONCOGENE RAS; SECONDARY; TREATMENT OUTCOME; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; CAMPTOTHECIN; CANADA; CETUXIMAB; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; GENES, RAS; HUMANS; KAPLAN-MEIER ESTIMATE; LEUCOVORIN; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; TREATMENT OUTCOME; UNITED STATES;

EID: 85021118379     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2017.7105     Document Type: Article

References (24)

1. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol. 1992;10(6): 896-903.
2. O'Dwyer PJ, Paul AR, Walczak J, Weiner LM, Litwin S, Comis RL. Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer. J Clin Oncol. 1990;8 (9):1497-1503.
3. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet. 2000;355(9209):1041- 1047.
4. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18(16):2938- 2947.
5. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol. 2004;22(2):229-237.
6. Grothey A, Sargent D, Goldberg RM, Schmoll H-J. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol. 2004;22 (7):1209-1214.
7. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractorymetastatic colorectal cancer. N Engl J Med. 2004;351(4): 337-345.
8. Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol. 2005;23(9):1803-1810.
9. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin formetastatic colorectal cancer. N Engl J Med. 2004;350(23):2335-2342.
10. Saltz LB, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy inmetastatic colorectal cancer: A randomized phase III study. J Clin Oncol. 2008;26 (12):2013-2019.
11. Lievre A, Bachet J-B, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol. 2008;26(3):374-379.
12. Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med. 2009;360(6): 563-572.
13. Hecht JR, Mitchell E, Chidiac T, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol. 2009;27 (5):672-680.
14. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205-216.
15. Bennouna J, Sastre J, Arnold D, et al; ML18147 Study Investigators. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): A randomised phase 3 trial. Lancet Oncol. 2013;14(1):29-37.
16. Heinemann V, vonWeikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): A randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(10):1065-1075.
17. Schwartzberg LS, Rivera F, Karthaus M, et al. PEAK: A randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2metastatic colorectal cancer. J Clin Oncol. 2014;32(21):2240-2247.
18. Modest DP, Stintzing S, vonWeikersthal LF, et al. Impact of subsequent therapies on outcome of the FIRE-3/AIO KRK0306 trial: first-line therapy with FOLFIRI plus cetuximab or bevacizumab in patients with KRAS wild-type tumors in metastatic colorectal cancer. J Clin Oncol. 2015;33(32):3718- 3726.
19. Venook AP, Niedzwiecki D, Innocenti F, et al. Impact of primary (1°) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance). http://meetinglibrary.asco.org/record/123617/abstract Presented June 25, 2016. Accessed May 26, 2017.
20. Shi Q, de Gramont A, Grothey A, et al. Individual patient data analysis of progression-free survival versus overall survival as a first-line end point formetastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database. J Clin Oncol. 2015;33(1):22-28.
21. Heinemann V, Niedzwiecki D, Pearline R, et al. Outcomes for FOLFIRI plus bevacizumab (BEV) or cetuximab (CET) in patients previously treated with oxaliplatin-based adjuvant therapy: A combined analysis of data from FIRE-3 and CALGB 80405. http://meetinglibrary.asco.org/record/112003/video Presented June 1, 2015. Accessed May 26, 2017.
22. O'Neil BH, Venook AP. Trying to understand differing results of FIRE-3 and 80405: does the first treatment matter more than others? J Clin Oncol. 2015;33(32):3686-3688.
23. Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21(11):1350-1356.
24. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-655.